Given the data and tweets, could you project whether the closing price of $nvs will grow or shrink at 2015-05-22? Please specify either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2015-05-08,-0.2,0.6,-0.2,1.3,1.3,-0.5,-0.2,0.2,0.2,-0.1,-0.5
2015-05-11,-0.5,0.6,-0.5,-0.5,-0.5,-0.3,0.2,0.7,0.7,0.5,0.0
2015-05-12,-0.2,0.4,-0.4,-0.0,-0.0,-0.2,0.1,0.6,0.6,0.6,0.1
2015-05-13,0.2,0.6,-0.1,0.3,0.3,-0.3,-0.2,0.3,0.3,0.3,-0.1
2015-05-14,0.3,0.3,-0.4,1.2,1.2,-1.0,-1.2,-1.0,-0.8,-0.8,-1.1
2015-05-15,-0.5,0.2,-0.8,-0.1,-0.1,-0.7,-1.0,-0.9,-0.6,-0.6,-0.8
2015-05-18,0.3,0.5,-0.3,0.3,0.3,-0.7,-1.3,-1.2,-0.8,-0.9,-1.0
2015-05-19,0.1,0.5,-0.1,-0.2,-0.2,-0.2,-0.9,-0.9,-0.6,-0.6,-0.7
2015-05-20,-0.3,0.3,-0.4,-0.3,-0.3,0.3,-0.4,-0.6,-0.3,-0.3,-0.3
2015-05-21,-0.3,0.3,-0.5,1.2,1.2,-0.8,-1.3,-1.6,-1.6,-1.5,-1.5

2015-05-08: lawsuits continue to delay $nvs's #zarxio.  $amgn doubles down on delay tactics.|rt AT_USER european commission approves novartis' lung cancer drug zykadia  $nvs #pharma|potential novartis ag $nvs tra
2015-05-12: physician views: which companies excel in #diabetes drug marketing and why?  $azn $jnj $lly $nvo $nvs $sny
2015-05-14: rt AT_USER #asco15 $clvs $azn egfrm t790m late-comer competition #1 -&gt; $nvs egf816:  54.5% orr
Answer:
Given the data and tweets, could you project whether the closing price of $nvs will grow or shrink at 2015-05-22? Please specify either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2015-05-08,-0.2,0.6,-0.2,1.3,1.3,-0.5,-0.2,0.2,0.2,-0.1,-0.5
2015-05-11,-0.5,0.6,-0.5,-0.5,-0.5,-0.3,0.2,0.7,0.7,0.5,0.0
2015-05-12,-0.2,0.4,-0.4,-0.0,-0.0,-0.2,0.1,0.6,0.6,0.6,0.1
2015-05-13,0.2,0.6,-0.1,0.3,0.3,-0.3,-0.2,0.3,0.3,0.3,-0.1
2015-05-14,0.3,0.3,-0.4,1.2,1.2,-1.0,-1.2,-1.0,-0.8,-0.8,-1.1
2015-05-15,-0.5,0.2,-0.8,-0.1,-0.1,-0.7,-1.0,-0.9,-0.6,-0.6,-0.8
2015-05-18,0.3,0.5,-0.3,0.3,0.3,-0.7,-1.3,-1.2,-0.8,-0.9,-1.0
2015-05-19,0.1,0.5,-0.1,-0.2,-0.2,-0.2,-0.9,-0.9,-0.6,-0.6,-0.7
2015-05-20,-0.3,0.3,-0.4,-0.3,-0.3,0.3,-0.4,-0.6,-0.3,-0.3,-0.3
2015-05-21,-0.3,0.3,-0.5,1.2,1.2,-0.8,-1.3,-1.6,-1.6,-1.5,-1.5

2015-05-08: lawsuits continue to delay $nvs's #zarxio.  $amgn doubles down on delay tactics.|rt AT_USER european commission approves novartis' lung cancer drug zykadia  $nvs #pharma|potential novartis ag $nvs tra
2015-05-12: physician views: which companies excel in #diabetes drug marketing and why?  $azn $jnj $lly $nvo $nvs $sny
2015-05-14: rt AT_USER #asco15 $clvs $azn egfrm t790m late-comer competition #1 -&gt; $nvs egf816:  54.5% orr
Answer:+Fall